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Abstract Loss of E-cadherin expression is causal to the de-
velopment of invasive lobular breast carcinoma (ILC). E-
cadherin loss leads to dismantling of the adherens junction
and subsequent translocation of p120-catenin (p120) to the
cytosol and nucleus. Although p120 is critical for the meta-
static potential of ILC through the regulation of Rock-
dependent anoikis resistance, it remains unknown whether
p120 also contributes to ILC development. Using genetically
engineered mouse models with mammary gland-specific in-
activation of E-cadherin, p120 and p53, we demonstrate that
ILC formation induced by E-cadherin and p53 loss is severely
impaired upon concomitant inactivation of p120. Tumors that
developed in the triple-knockout mice were mostly basal
sarcomatoid carcinomas that displayed overt nuclear atypia
and multinucleation. In line with the strong reduction in ILC
incidence in triple-knockout mice compared to E-cadherin and
p53 double-knockout mice, no functional redundancy of p120
family members was observed in mouse ILC development, as
expression and localization of ARVCF, p0071 or δ-catenin
was unaltered in ILCs from triple-knockout mice. In conclu-
sion, we show that loss of p120 in the context of the p53-
deficient mouse models is dominant over E-cadherin inactiva-
tion and its inactivation promotes the development of basal,
epithelial-to-mesenchymal-transition (EMT)-type invasive
mammary tumors.
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Introduction
Loss of E-cadherin is a driver event in cancer that has been
linked to tumor development and progression [1]. In breast
cancer, mode and timing of E-cadherin inactivation appears
to determine tumor type and etiology [2]. In diffuse gastric
cancer and invasive lobular breast cancer (ILC), E-cadherin
loss is an early and causative lesion [3–7], while most other
tumors show loss of E-cadherin during later stages of disease
progression (reviewed in: [8]). Cre-lox based conditional
mouse models have demonstrated that mutational inactivation
of E-cadherin in the mammary gland is not tolerated, leading
to clearance of E-cadherin negative cells [9, 10]. However, in
the context of p53 deficiency, E-cadherin loss induces the
formation and progression of mouse ILC (mILC), which
mimics its human counterpart in phenotype and metastatic
dissemination [10, 11].
As an integral part of the adherens junction (AJ), E-
cadherin is responsible for homotypic cell-cell connections
[12]. E-cadherin stability and turnover is regulated by p120-
catenin (p120), an armadillo-repeat containing molecule that
binds directly to the E-cadherin juxtamembrane domain at the
cell cortex [13, 14]. In ILC cells, loss of E-cadherin results in a
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translocation of p120 to the cytosol [5, 15, 16], where it con-
trols constitutive activation of autocrine induced RhoA-Rock
signaling, which underpins actomyosin-dependent anoikis re-
sistance and subsequent tumor dissemination [17, 18]. In con-
trast, p120 expression patterns in ductal breast cancers are not
related to E-cadherin expression [19]. Localization of p120
can therefore be used to aid differential diagnosis between
ductal and lobular breast cancer [16, 20].
Three closely related p120 family members can be found in
vertebrates: ARVCF, δ-catenin (CTNND2) and p0071 (PKP4)
[21]. Although these family members can also bind and sta-
bilize E-cadherin [22], their redundancy in relation to each
other has only been partially addressed. Of note, p120 appears
to have evolved together with the non-neural classical
cadherins, separately fromARVCF, δ-catenin and p0071, sug-
gesting different functional roles [21].
Although loss of p120 leads to a dissociation of the AJ,
conditional loss of p120 in the mouse mammary gland in
combination with p53 does not lead to ILC formation but
instead induces the formation of high-grade metaplastic-type
ductal tumors that metastasize to lungs and lymph nodes [23].
These observations showed that, although the effect of AJ
inactivation is the acquisition of tumor invasion and metasta-
sis, the phenotypical outcome of the resulting tumor is deter-
mined by the AJ member that is inactivated. To study the
contribution of p120 to the development of ILCwe introduced
a p120 conditional allele [24] into the mILC mouse model
[11], and observed that concomitant loss of p120 at the early
stages of tumor development largely prevents the formation of
mouse ILC (mILC). Our studies indicate that p120 is a crucial
factor in ILC etiology.
Results
Early Loss of p120 Constrains Formation of ILC
inWcre;Cdh1F/F;Trp53F/F Female Mice
Using two independent tissue-specific Cre drivers (K14cre
and Wcre) it was previously shown that combined loss of E-
cadherin (encoded by Cdh1) and p53 (encoded by Trp53) in
mouse mammary epithelium results in the formation of tu-
mors that resemble human invasive lobular carcinoma (ILC)
[10, 11]. To study the contribution of p120 to the development
of ILCwe introduced a previously generated conditional p120
(Ctnnd1F) allele [24] into the Wcre;Cdh1F/F;Trp53F/F ILC
model [11] to produce Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F
and Wcre;Ctnnd1F/F;Cdh1F/F;Trp53F/F (Triple Knock Out:
TKO) female mice that were followed for tumor formation.
Although heterozygous inactivation of p120 in the mILC
model influenced the median tumor-free survival (T50; 214
versus 178 days, p = 0,0146), TKO female mice showed sim-
ilar T50 values when compared to Wcre;Cdh1F/F;Trp53F/F
mice (188 versus 187 days; p = 0.6627) (Fig. 1). We also
observed no significant T50 differences when comparing
Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F versus TKO female mice
(Fig. 1).
To explore if p120 controls ILC development we examined
tumor histopathology based on H&E staining and diagnosed
all primary tumors (Table 1, and Supplementary Table 1).
In teres t ingly, heterozygous dele t ion of p120 in
Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F female mice resulted in a
marked increase in the incidence of solid ILC compared to
Wcre;Cdh1F/F;Trp53F/F control mice (47.1 % versus 4.3 %;
p = 0.02, Supplementary Table 1 and [11]). Solid-type mILC
is a rare ILC subtype characterized by large solid sheets of
uniform cells with round nuclei and little stroma, and was only
rarely diagnosed in theWcre;Cdh1F/F;Trp53F/F control cohort
(Derksen, 2011). We did not observe statistically significant
changes regarding formation of ILC, solid adenocarcinoma
(AC) or solid carcinoma/carcinosarcoma (SC/CS) which were
characterized by a metaplastic and biphasic histology which
comprised mesenchymal elements (Fig. 2) [11, 25].
Furthermore, the percentage of invasive tumors or tumor dis-
semination (lungs or lymph nodes) did not change upon het-
erozygous deletion of p120 (Table 1). As with the
Wcre;Cdh1F/F;Trp53F/F model we detected occasional tumor
dissemination to the abdominal organs, including spleen and
liver, in Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F and TKO female
mice (1 and 2 cases respectively, Supplementary Table 1 and
Fig. 3).
Homozygous deletion of p120 in TKO female mice result-
ed in a tumor spectrum of mainly SC/CS lesions (p = 0.0094
compared toWcre;Cdh1F/F;Trp53F/Fmice; Table 1 and Fig. 2)
that showed a metaplastic and biphasic histology with overt
nuclear atypia and multinucleation. Interestingly, formation of
mouse ILC was nearly absent upon homozygous p120 loss
(p < 0.0001 compared to Wcre;Cdh1F/F;Trp53F/F mice;
Table 1). All tumors that developed in the female TKO cohort
lacked p120 and E-cadherin expression (Fig. 2 and
Supplementary Table 1). In contrast, all tumors from the het-
erozygousWcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F mice expressed
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Fig. 1 Tumor incidence in Wcre females carrying conditional Ctnnd1,
Cdh1 and Trp53 alleles. Kaplan-Meier tumor-free survival curves are
shown for mammary tumors from Wcre;Cdh1F/F;Trp53F/F (red curve)
TKO (black curve) andWcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F (green curve).
Mice were sacrificed when tumors reached an average diameter of 10 mm
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pattern of p120 in Wcre;Cdh1F/F;Trp53F/F mice (Fig. 2 and
Supplementary Table 1).We did not detect overt differences in
cytokeratin (CK) and vimentin expression in tumors from the
Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F and TKO cohort com-
p a r e d t o t u m o r s t h a t h a d d e v e l o p e d i n
Wcre;Cdh1F/F;Trp53F/F;Trp53F/F mice (Supplementary
Table 1). Overall, tumors showed amutually exclusive expres-
sion pattern of CK8 and CK14, while vimentin was expressed
at low levels, mostly in the sarcomatoid/mesenchymal-type
tumors (SC/CS) (Fig. 4). None of the tumor types expressed
the estrogen or progesterone receptor (ER, PR), in line with
previous observations that ER and PR are not expressed in
tumor s t ha t deve loped in Wcre ; Trp53F / F and
Wcre;Cdh1F/F;Trp53F/F female mice [10, 11]. The metastases
that formed in Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F and TKO
displayed marker expression patterns similar to the primary
tumors (Supplementary Fig. 1 and Supplementary Table 2).
Taken together, our data show that early inactivation of p120
in the context of combined E-cadherin and p53 loss largely
prevents formation of mouse ILC, and leads to the formation
of high-grade basal mammary tumors that are characterized by
a more prominent expression of the basal markers CK14 and
vimentin, metaplastic and sarcomatoid histology and strong
nuclear atypia.
p120 Family Members Lack Functional Redundancy
during Mammary Carcinoma Development
Because we diagnosed three p120-negative tumors as mILC
in female TKO mice, we wondered whether compensation by
one or more p120 family members could have accounted for
the formation of these sporadic ILC tumors. Given that
ARVCF, δ-catenin and p0071 are structurally related to p120
and share several functions at the membrane and in the cyto-
sol, we investigated the effects of p120 loss on the expression
and localization of these family members in mILC. We started
by testing specificity of the antibodies by assessing expression
in normal mammary epithelial ductal structures using immu-
nofluorescence. Expression of ARVCF, δ-catenin and p0071
in normal ducts showed partial overlap with p120 at the plas-
ma membrane (Fig. 5a). However, we also observed ARVCF,
δ-catenin and p0071 expression in the cytoplasm and nucleus
(Fig. 5a, left panels).
Next we determined the expression of ARVCF, δ-catenin
and p0071 in the different tumor sub-types from TKO mice,
which were compared to tumors fromWcre;Cdh1F/F;Trp53F/F
mice. In accordance with previous findings we observed cy-
tosolic and nuclear p120 expression in mILC and SC/CS tu-
mors from Wcre;Cdh1F/F;Trp53F/F mice (Fig. 5b-d, top lanes
and Supplementary Fig. 2), while in TKO mice p120 expres-
sion was only observed in stromal cells (Fig. 5 and
Supplementary Fig. 2, bottom lanes). ARVCF, δ-catenin and
p0071 showed diffuse localization patterns regardless of tu-
mor type or p120 status (Fig. 5 and Supplementary Fig. 2).
Based on these results and the fact that mILC incidence is
drastically reduced in TKO tumors, we conclude that
ARVCF, p0071 or δ-catenin do not play redundant roles in
mammary tumor formation in TKO mice.
Discussion
Cytoplasmic p120 is a hallmark of lobular breast cancer [5,
15–17]. Here we examined the contribution of p120 to ILC
development in mice, and demonstrate that p120 is critical for
the development of invasive lobular carcinoma in mice.
Previous data demonstrated that dual inactivation of p120
and p53 in the mouse mammary gland leads to sarcomatoid,
epithelial-to-mesenchymal-transition (EMT)-like mammary
carcinomas. These p120 negative mammary tumors presented
with anaplastic histological features and expression of basal
markers such as CK14 and/or vimentin [23]. In this study we
have introduced conditional p120 alleles into the WAP-cre
driven mouse ILC model [11]. Mouse ILC (like most condi-
tional mouse models of human breast cancer) is an ER nega-
tive tumor type [10, 11], and as such models a minority of
human ILC that is either ER negative or non-responsive to ER
antagonists treatment. Moreover, because mouse ILC appears
refractory to cisplatin, docetaxel or doxorubicine (our unpub-
lished results), we use mouse ILC as a model for advanced-
stage, metastatic and chemo-refractory human ILC. In con-
trast, poorly differentiated basal tumors, which we also ob-
serve in tumors lacking p120, are usually devoid of ER




Cdh1F/F;Trp53F/F (n = 17)
p value
(vs.Wcre;Cdh1F/F;Trp53F/F)
TKO (n = 21) p value
(vs.Wcre;Cdh1F/F; Trp53F/F)
Invasive 20 (86 %) 15 (88 %) p = 1.0000 19 (90 %) p = 1.0000
Metastasis 17 (74 %) 7 (41 %) p = 0.0531 10 (48 %) p = 0.1210
AC 0 (0 %) 1 (6 %) p = 0.4250 0 (0 %) -
SC/CS 16 (70 %) 11 (65 %) p = 1.0000 21 (100 %) p = 0.0094
mILC 17 (74 %) 8 (47 %) p = 0.1074 3 (14 %) p < 0.0001
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expression [26]. Although Cre expression in our WAPcre
mouse models is mostly restricted to luminal cells, basal duc-
tal cells (CK14POS/CK8NEG) occasionally also express Cre
[11]. Because Cre expression is already evident in virgin
Wcre;Cdh1F/F;Trp53F/F female mice, and tumor incidence
occurrs independent of parity [11], tumorigenesis in these
models is most likely instigated in a mammary progenitor cell
type. Because of these data and the fact that most mILC in
Wcre;Cdh1F/F;Trp53F/F female mice predominantly
expressed CK8, we assume that p120 could play a role in
the progression of a luminal-type cancer-initiating cell.
Indeed, we show that early dual loss of E-cadherin and p120
almost completely prevents development of mILC.
Furthermore, the mILCs that arose in a minority of TKO fe-
male mice, displayed biphasic features and consisted mostly
of mesenchymal SC/CS tumor cells. Finally, all other tumors
that developed in p120 knockout mice were diagnosed as


































Fig. 2 E-cadherin and p120 expression in the mammary tumor spectrum. a-
b Sections showing representative examples for mouse ILC (mILC) (a) and
solid carcinoma/carcinosarcoma (SC/CS) (b) for the different genotypes stud-
ied. Sections were stained for E-cadherin (middle panels) and p120 (bottom
panels). In TKO tumors p120 is only expressed by stromal cells (arrows).
Nuclear atypia is present in p120 negative tumors (arrow heads). The middle
and bottom panels are magnifications that correspond to the area indicated in
the upper panels. Size bar =25μm. cDistribution ofAC (green), mILC (blue)
and SC/CS tumors (orange) in mammary glands ofWcre;Cdh1F/F;Trp53F/F,
Wcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F and TKO female mice
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p120 predisposes mammary progenitors to a basal lineage
commitment and prevents the formation of luminal type ILC.
In spite of this shift towards a basal tumor spectrumwe still
observed occasional formation of classical mILC lesions in
TKO female mice. TKO mILC expressed the luminal CK8
marker, which might be a result of p120 deletion in a
luminal-type committed progenitor. We studied expression
of ARVCF, p0071 and δ-catenin in TKOmILC lesions, which
yielded no indication that p120 loss induced a change in ex-
pression levels or localization of these proteins. While this
does not formally exclude the possibility of functional redun-
dancy, we conclude that this is not a likely scenario underpin-
ning the occasional formation of ILC in TKO female mice.
Also the fact that inactivation of p120 in the context of p53
loss leads to basal-type invasive and metastatic mammary
tumors, renders a redundant role for these p120 family mem-
bers highly unlikely.
Forced dual inactivation of p120 and p53 at the early stages
of tumor development might induce two scenarios. First, p120
loss induces an EMT leading to high-grade, basal-type tumors
that show a large degree of nuclear atypia and metastasize to
lungs and lymph nodes. This process is dominant over E-
cadherin loss and its downstream biochemical consequences,
preventing ILC formation in triple-knockout mice (Fig. 6).We
envisage a second scenario, in which E-cadherin loss triggers
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Fig. 3 Metastases of mouse
tumors from the TKO mouse
model. Tumor dissemination
showing metastasis into the
axillary lymph node (a), lungs
(b), liver (c) and spleen (d).
Primary tumors were diagnosed
as carcinosarcoma. Dotted lines
outline the metastatic area (M).
The bottom panels are
magnifications that correspond to
the area indicated in the top





Wcre;Cdh1F/F;Trp53F/F TKO Wcre;Cdh1F/F;Trp53F/F TKO
mILC SC/CSFig. 4 Comparative
immunohistochemistry of
mammary tumors. Analysis of
marker expression in tumor types
of Wcre;Cdh1F/F;Trp53F/F and
TKO mice. Luminal cells were
identified by CK8 expression,
while CK14 staining was
performed to detect basal cells.
Vimentin (Vim) was used as a
mesenchymal marker. The
bottom panels are magnifications
that correspond to the area
indicated in the top panels. Size
bar =50 μm
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and progression. Concomitant inactivation would then re-
move p120 from the ILC-initiating cells and enforce a p120-
negative basal breast cancer phenotype. We hypothesize that
either scenario can contribute equally to the observed tumor
phenotypes.
In human breast cancer, loss of p120 is observed in approx-
imately 15–20 % of invasive ductal carcinomas, with a
marked complete loss of p120 expression inmetaplastic breast
cancer [17, 23, 27–29]. Despite the fact that conditional p120
inactivation in the mouse mammary gland induces invasive
mammary carcinomas, human p120-negative breast cancers
are mostly devoid of inactivating CTNND1 mutations and
do not show silencing through promotor methylation.
Moreover, p120 is mostly lost focally in human IDC, indicat-
ing that p120 inactivation is a late event in breast cancer. This
notion is supported by the fact that (i) p120 loss in the absence
of additional oncogenic mutations will negatively impact both
luminal and myoepithelial cells of the mammary gland
through destabilization of all classical cadherins, and (ii)
p120 controls key biological processes such as activation of








Fig. 6 Inactivation of E-cadherin or p120 has divergent consequences on
mammary tumor etiology. WAP-cre dependent stochastic loss of p53
predisposes tumor-initiating cells to the development of non-metastatic
luminal adenocarcinoma (AC) and basal solid carcinoma/carcinosarcoma
(SC/CS) [11]. Inactivation of E-cadherin in this context drives the luminal
tumor spectrum towards metastatic invasive lobular cancer (ILC). In con-
trast, p120 ablation tilts the balance towards formation of basal EMT-type
SC/CS. In general, conditional loss of either E-cadherin or p120 results in
invasive and metastatic tumors. Inactivation of the adherens junction
through p120 loss is dominant over E-cadherin loss in TKOmice, largely
preventing ILC development, and driving the formation of EMT-type
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Fig. 5 Expression of p120 family members in mILC. a p120 family
member expression (left panels, green) in the mouse mammary gland.
Expression of p120 is depicted in the middle panels (red). b-d
Immunofluorescence showing expression of p120 (red) and its family
members (green) ARVCF (b), δ-catenin (c) and p0071 (d) in mILCs from
Wcre;Cdh1F/F;Trp53F/F (top panels) and TKO mice (bottom panels).
DAPI (blue) was used to visualize nuclei. The merged images are shown
in the right panels. Size bar =25 μm
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transcriptional programs through Kaiso [30–32]. Thus, al-
though p120 loss can propel tumor progression in both cell
lineages, this probably only occurs during later stages of hu-
man breast cancer progression.
In sum, we show that loss of p120 promotes the develop-
ment of EMT-type basal invasive mammary tumors. In a p53-
deficient context, p120 loss is dominant over E-cadherin in-
activation in driving mammary tumorigenesis, thus largely
preventing the formation of ILC. Conversely, in the context
of early mutational E-cadherin activation, p120 will take cen-
ter stage to unveil its oncogenic role to drive anchorage-
independence and metastatic ILC.
Materials and Methods
Generation and Genotyping
ofWcre;Ctnnd1F/+;Cdh1F/F;Trp53F/F and TKO Mice
Mammary-specific p120 knockout mice were generated by
crossing the conditional Ctnnd1F-allele [24] onto the
Wcre;Cdh1F/F;Trp53F/F mice [11]. Genotyping was done as
described previously [10, 11, 24]. Mice were euthanized when
tumors reached a diameter of 10 mm. Date of sacrifice was
used for the tumor-free survival analyses. Histology of the
primary tumor was used as diagnosis while full autopsies were
performed to detect additional tumors and metastases. All an-
imal experiments were approved by the Animal Ethics
Committee (DEC) of the Netherlands Cancer Institute
(DEC-A: 09,014, DEC-B: 2/6, work protocol 3620.1939).
Wcre;Cdh1F/F;Trp53F/F mouse data were described previous-
ly [11].
Antibodies
Primary antibodies used include mouse anti-p120-catenin
(1:500, BD Biosciences 610134), mouse anti-E-cadherin
(1:200, BD Biosciences 610182) rat anti-CK8 (1:125,
Developmental Studies Hybridoma Bank, Troma-1), rabbit
anti-CK14 (1:10.000, Covance, PRB-155P), guinea pig anti-
vimentin (1:400, Fitzgerald, 20R-VP004), rabbit anti-δ-
catenin (EMD-millipore, 07–259), guinea pig anti-ARVCF
(1:100, previously used in [33]), guinea pig anti-p0071
(1:100, previously used in [33]).
Secondary antibodies used were rabbit anti-guinea pig
(DAKO, p0141), HRP conjugated rabbit anti-rat (DAKO
p0450 ) , po l y HRP an t i - r a bb i t ( Immuno l og i c ,
DPVR500HRP), poly HRP anti -mouse/rabbi t / ra t
(Immunologic, DPVO500HRP), Alexa568 conjugated anti-
mouse (1:500, Invitrogen, A11031) and Alexa488 conjugated
anti-rabbit (1:500, Invitrogen, A11034).
Immunohistochemistry and Immunofluorescence
Tissues were fixed in 4 % formaldehyde for 24 h. After dehy-
dration, tissues were embedded in paraffin and cut into 4 mm
sections. Slides were rehydrated and endogenous peroxidase
was blocked in 1.5 % H2O2 containing buffer. Depending on
the primary antibody used, antigen retrieval was performed
either by proteinase K (DAKO) treatment for 5 min (for
vimentin and CK8) or by boiling of the slides in 10mM citrate
buffer (pH 6.0) for 20 min (for E-cadherin and p120). For
CK14 no additional procedure for antigen retrieval was per-
formed. Primary antibody incubation took place overnight at
4 °C, followed by staining with HRP-conjugated secondary
antibodies for 30 min. The substrate was developed using
diaminobenzidine (DAB) followed by hematoxylin staining.
Finally, sections were dehydrated and mounted with pertex for
microscopic examination. For immunofluorescence, sections
were incubated with Alexa conjugated secondary antibodies
for 2 hours followed by DAPI incubation to stain for DNA.
The slides were mounted using Vectashield fluorescence
(Vector Labs) and images were collected by confocal laser
microscopy using a Zeiss LSM510 Meta.
Statistical Analysis
Statistics were calculated using Graphpad Prism 5. For sur-
vival analysis, the Log-Rank test was used. For analysis of
growth patterns, metastasis and histological types, Fisher’s
exact test was used. P values <0.05 were considered statisti-
cally significant.
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